Request Deal Involvement

Sanofi completed the acquisition of Kymab from Malin and Schroder for $1.1bn.

Identify your role

Select the side you represented in this transaction, and provide your current job title.

Service Providers

Consilium Strategic Communications

pr advisors

Consilium Strategic Communications

Goodwin Procter

legal advisors

Goodwin Procter

JP Morgan

financial advisors

JP Morgan

Weil Gotshal and Manges

legal advisors

Weil Gotshal and Manges

Powerscourt

pr advisors

Powerscourt

Liberum Capital

brokers

Liberum Capital

Davy Corporate Finance

brokers

Davy Corporate Finance

or

Principals

KYMAB

target

KYMAB

SANOFI SA

bidder

SANOFI SA

MALIN CORPORATION PLC

vendor

MALIN CORPORATION PLC

SCHRODER UK PUBLIC PRIVATE TRUST PLC

vendor

SCHRODER UK PUBLIC PRIVATE TRUST PLC

BILL AND MELINDA GATES FOUNDATION

vendor

BILL AND MELINDA GATES FOUNDATION

ORI CAPITAL

vendor

ORI CAPITAL

THE WELLCOME TRUST

vendor

THE WELLCOME TRUST

LIFEARC VENTURES

vendor

LIFEARC VENTURES

SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO

vendor

SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO

Principals or Service Provider not listed?Add missing Service Provider or Principal

Enter your Job Title on this deal

This title will appear on your profile next to this deal involvement.


To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:

All rights reserved. Copyright © 2025 Datasite

MergerLinks - Request Credit - Sanofi completed the acquisition of Kymab from Malin and Schroder for $1.1bn.